By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ensysce Biosciences Inc. 

1430 O'Brien Drive
Suite G
Menlo Park  California  94025  U.S.A.
Phone: n/a Fax: n/a



Start Up

Company News
Ensysce Biosciences Inc. Attending NIH Conference: Cutting Edge Science Meeting Series To End The Opioid Crisis: Development Of Safe, Effective, Non-Addictive Pain Treatments 6/12/2017 6:28:49 AM
Ensysce Biosciences Inc. Publishes Manuscript Describing The In Vitro Abuse Deterrence Of Oxycodone Prodrug, PF614 4/3/2017 8:36:30 AM
Ensysce Biosciences Inc. To Present Initial Phase 1 Data On Abuse Deterrent Opioid, PF614, At Biotech Showcase 2017 1/3/2017 9:43:05 AM
Ensysce Biosciences Inc. Initiates Phase 1 Clinical Trial To Study PF614, BIO-MD Prodrug Of Oxycodone 12/2/2016 11:18:45 AM
Ensysce Biosciences Inc. And Signature Therapeutics Merger 1/19/2016 9:45:21 AM
Ensysce Biosciences Inc. Demonstrates Carbon Nanotube Delivery Of RNA To PBMCs 7/8/2015 12:05:42 PM
Ensysce Biosciences Inc. Receives Notice Of Allowance For U.S. Patent For Delivery Of siRNA 3/7/2014 8:51:24 AM
Ensysce Biosciences Inc. Receives Small Business Grant From National Institutes of Health (NIH) to Optimize Single Walled Carbon Nanotube Formulation for Therapeutic Delivery of siRNA 9/25/2012 10:02:30 AM
Ensysce Biosciences Inc. Completes Qualifying Financial Transaction Matching Emerging Technology Funds from the State of Texas 6/6/2012 9:57:07 AM
Ensysce Biosciences Inc. Publishes Data on the Use of Carbon Nanotube to Aid the Delivery of siRNA 2/14/2012 6:01:17 AM